Key Stats for Eli Lilly Stock
- Price Change for $LLY stock: 5.85%
- Current Share Price: $736
- 52-Week High: $969
- $LLY Stock Price Target: $888
What Happened?
Eli Lilly (LLY) stock surged close to 6% on Tuesday following the announcement of positive Phase 3 trial results for its experimental oral weight-loss pill, orforglipron.
The healthcare giant reported that its ATTAIN-2 trial met all primary and key secondary endpoints, with patients taking the highest dose (36 milligrams) losing an average of 22.9 pounds or 10.5% of their body weight over 72 weeks.
The oral GLP-1 treatment also delivered significant improvements in diabetes management, with A1C glucose levels declining by an average of 1.8%.
Additionally, 75% of participants taking the highest dose achieved an A1C level of 6.5% or below, meeting the American Diabetes Association’s threshold for diabetes.
The drug also showed benefits for cardiovascular risk factors, including cholesterol levels, blood pressure, and inflammatory markers.
Lilly stated it now has the complete clinical data package needed to begin global regulatory submissions for orforglipron, positioning the company to potentially capture significant market share in the growing obesity treatment market with a more convenient oral alternative to injectable therapies.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free!) >>>
What the Market Is Telling Us About Eli Lilly Stock
The positive market reaction to LLY stock reflects investor enthusiasm for Lilly’s potential to expand access to GLP-1 therapies through an oral formulation, addressing a key limitation of current injectable treatments.
However, the weight loss results, while significant, were notably lower than those achieved by injectable GLP-1 medicines, such as Lilly’s own Zepbound and Novo Nordisk’s Wegovy.
The trial results also revealed concerning side effect profiles, with high rates of gastrointestinal issues, including nausea (36.4%), vomiting (23.1%), and diarrhea (27.4%) at the highest dose.
Moreover, discontinuation rates were similarly high between the active treatment and placebo groups, suggesting tolerability challenges that could impact real-world adoption.
Despite these limitations, analysts view the oral formulation as a competitive advantage that could help Lilly maintain its leadership position in the rapidly growing incretin market.
The company’s strong Q2 performance, with 38% revenue growth driven by Mounjaro and Zepbound sales, provides a solid foundation for continued expansion.
Management has raised full-year guidance and expects to produce 1.8 times more incretin doses in the second half of 2025 compared to the prior year, addressing supply constraints that have limited market growth.
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
